In my opinion, it’s game over for the bears. A first in class...

In my opinion, it’s game over for the bears. A first in class MSC therapy with opportunities galore, proprietary potency assays for back, heart and acute sr ghvd/IBD, ….clinical trial and safety data going back 20 years in several different indications, and an pretty impenetrable IP moat…. I would expect at least ten additional indications to receive at least accelerated approval status over the next 10 years . Based on that assumption, I see little reason why Mesoblast cannot reach one hundred to three hundred times its current value within 7-10 years if it also gets a couple of blockbuster indications validated at the same time. ..but then again there are always black swan events beyond my comprehension. Alternatively, a major Pharma may just try to see what price will tempt the current board. If you want to argue with me fine . I just thought it was time to let the genie out of the bottle. Good luck everyone . OP




Please do not rely on the facts or opinions expressed in the above post when making an investment decision . I am not currently inebriated. I own shares and options, which i may from time to time trade and will personally benefit massively from positive price movements in the stock. I had previously lost substantial sums for failing to account for dilution from funding shortfalls caused by delays over timelines or allowing for very slow responses from regulators . I believe the above headline has removed a significant barrier to Mesoblast gaining label extensions for a whole host of orphan diseases owing to exceptional early stage signs of efficacy.